GSK Breakout Trade – Clean Setup AheadPattern: Bullish breakout from descending wedge
Entry Zone: Around $4.83–$4.97
Stop Loss: Just below $4.70 (trendline + horizontal support)
Target: $5.18 (green resistance level)
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
40.75 MXN
68.60 B MXN
835.91 B MXN
2.01 B
About GSK PLC ORD GBP0.3125
Sector
Industry
CEO
Emma N. Walmsley
Website
Headquarters
London
FIGI
BBG00JX0NSM0
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Related stocks
$GSKA potential "ABC" pattern has been located here at a level where two previous support levels were broken. Price is near the 11-2023 support level. Looking for a retracement here to two targets overtime.
GSK 1-2 wk swing IdeaNYSE:GSK has set of a daily trigger with a 5/10 ema crossover after a positive earnings report.
During my planning for this idea, I needed to zoom WAY out to the monthly chart in order to understand these levels a bit more. Screen shot of the monthly below:
It turns out that last week's close
GSKNot a recommendation. Held this for a while with very little movement, now GSK as started going up, div yield is over 3.3%
Long GSK - Euro Drug Hype Cycle approachesPlaying short term trade presuming positive news in a week or two.
Shares would return to the range highs near $37.00
Ex-Dividend Date later this week
GSK (GSK) Outperformed Market ReturnsIn the latest trading session, GSK (GSK) closed at $37.10, marking a +1.23% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 0.39%.
Prior to today's trading, shares of the dru
GSK looking bullish! Buy volume at resistance at this point in the falling channel should help propel the price to an initial measured target if $47 which would be thr breakout point of an even bigger bullish macro setup.
GSK with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for GSK after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
Long Glaxo Smith Kline (NAS:GSK) looks very good risk returnUsing longer term Auction Market Theory to construct longer term meaningful #VolumeProfiles can sometimes provide exceptional risk reward setups.
One has just popped up in GSK according to my read anyway.
Now price has returned into the longer term Value Area there's a very good chance price will
$GSK: Weekly trend signalGreat reward to risk in this weekly chart setup in $GSK, worth a shot, you can probably play it with options to not allocate too much capital in this idea and have limited downside risk. An ITM put spread or some kind of Iron Butterfly OTM can both reap the passage of time profiting from Theta drop
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GSK6023691
GlaxoSmithKline Capital Plc 4.315% 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035Yield to maturity
—
Maturity date
Apr 15, 2035
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043Yield to maturity
—
Maturity date
Mar 18, 2043
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030Yield to maturity
—
Maturity date
Apr 15, 2030
GSK6023692
GlaxoSmithKline Capital Plc FRN 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038Yield to maturity
—
Maturity date
May 15, 2038
XS255381768
GSK CAP B.V. 22/27 MTNYield to maturity
—
Maturity date
Nov 28, 2027
XS293369143
GSK CAP B.V. 24/31 MTNYield to maturity
—
Maturity date
Nov 19, 2031
XS217060184
GLAXOSM.CAP. MTN 20/28MTNYield to maturity
—
Maturity date
Oct 12, 2028
XS182282812
GLAXOSM.CAP. MTN 18/26MTNYield to maturity
—
Maturity date
May 21, 2026
XS168152035
GLAXOSM.CAP. MTN 17/29Yield to maturity
—
Maturity date
Sep 12, 2029
See all GSK/N bonds
Curated watchlists where GSK/N is featured.
Female-led stocks: Who rules the world?
34 No. of Symbols
UK stocks: Best of British
28 No. of Symbols
See all sparks
Frequently Asked Questions
The current price of GSK/N is 715.00 MXN — it has increased by 0.85% in the past 24 hours. Watch GSK PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange GSK PLC stocks are traded under the ticker GSK/N.
GSK/N stock has risen by 3.72% compared to the previous week, the month change is a −3.02% fall, over the last year GSK PLC has showed a −5.72% decrease.
We've gathered analysts' opinions on GSK PLC future price: according to them, GSK/N price has a max estimate of 1,262.60 MXN and a min estimate of 568.55 MXN. Watch GSK/N chart and read a more detailed GSK PLC stock forecast: see what analysts think of GSK PLC and suggest that you do with its stocks.
GSK/N stock is 2.83% volatile and has beta coefficient of 0.28. Track GSK PLC stock price on the chart and check out the list of the most volatile stocks — is GSK PLC there?
Today GSK PLC has the market capitalization of 1.52 T, it has increased by 4.82% over the last week.
Yes, you can track GSK PLC financials in yearly and quarterly reports right on TradingView.
GSK PLC is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
GSK/N earnings for the last quarter are 23.19 MXN per share, whereas the estimation was 21.96 MXN resulting in a 5.58% surprise. The estimated earnings for the next quarter are 23.23 MXN per share. See more details about GSK PLC earnings.
GSK PLC revenue for the last quarter amounts to 199.10 B MXN, despite the estimated figure of 196.90 B MXN. In the next quarter, revenue is expected to reach 203.84 B MXN.
GSK/N net income for the last quarter is 36.16 B MXN, while the quarter before that showed 41.90 B MXN of net income which accounts for −13.71% change. Track more GSK PLC financial stats to get the full picture.
Yes, GSK/N dividends are paid quarterly. The last dividend per share was 7.89 MXN. As of today, Dividend Yield (TTM)% is 3.94%. Tracking GSK PLC dividends might help you take more informed decisions.
GSK PLC dividend yield was 4.53% in 2024, and payout ratio reached 94.89%. The year before the numbers were 3.87% and 47.48% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 24, 2025, the company has 68.63 K employees. See our rating of the largest employees — is GSK PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK PLC EBITDA is 223.94 B MXN, and current EBITDA margin is 26.18%. See more stats in GSK PLC financial statements.
Like other stocks, GSK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK PLC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK PLC stock shows the sell signal. See more of GSK PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.